Alloplex Biotherapeutics has identified cancer tumor types responsive to its lead technology platform, SUPLEXA, in a single-agent study.
Topic: Clinical News
-
March 27, 2024
Alloplex set to validate crucial immunotherapy hypothesis and expands corporate structure with advisory panel.
Read More -
January 10, 2024
Naturally Occurring Immune Cells may push through where CAR T cells fall short, reports Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News recently published a feature story entitled ‘Immune Cell Therapy May Become More Naturalistic'.
Read More -
December 15, 2022
Alloplex opens third prestigious site for SUPLEXA-101 first-in-class cellular therapy trial in oncology patients
Southern Oncology Clinical Research Unit in Adelaide joins Cancer Research SA, also in Adelaide, and Gallipoli Medical Research Foundation of Brisbane for the Phase 1 trial of Alloplex Biotherapeutics' autologous SUPLEXA cell immunotherapy.
Alloplex Biotherapeutics today announced the opening of the third site in its first-in-human clinical trial of SUPLEXA: Southern Oncology Cancer Research Unit ‘SOCRU’. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived from patient peripheral blood mononuclear cel...
Read More